for Skin Cancers
Personalized circulating tumor DNA (ctDNA) testing to inform the management of skin cancers.
Identify Treatment Response and Recurrence Early
Monitor Treatment Response in Skin Cancers
Understanding if immunotherapy is working can be a clinical challenge
The Signatera™ Residual Disease Test can help assess treatment effectiveness, clarify indeterminate imaging, and identify exceptional responders to help you make the most informed decisions for your patients with skin cancer.1,2
Read the Published Data
Read how Signatera™ combined with standard imaging can predict immunotherapy response as early as 6 weeks into treatment.1
Review data demonstrating that ctDNA status is associated with risk of relapse in patients with stage III melanoma.3
Merkel Cell Carcinoma
Learn how Signatera™ can be used as a predictive biomarker regardless of MCPyV status.2
Personalize the Skin Cancer Treatment Journey
Partner with Natera to get comprehensive and streamlined genomic testing results to support individualized care.
|Signatera™||Highly sensitive and personalized tumor-informed test for molecular residual disease (MRD) detection|
|Altera™||Comprehensive tissue-based genomic profiling for clinically relevant somatic mutations/biomarkers (eg BRAF, CDKN2A, NRAS, TMB) with no additional sample when ordered with Signatera|
|Empower™||Germline genetic test for commonly screened genes in melanoma (eg BRCA1/BRCA2, TP53, CDKN2A, CDK4, BAP1, PTEN, MITF)|
Learn More About Signatera in Skin Cancers
After Steven was diagnosed with metastatic melanoma, his oncologist used Signatera™ to track his ctDNA levels. Watch Steven’s story to learn how Signatera helped him rediscover hope.
Is Signatera™ right for your patients with skin cancer?
1Bratman SV, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1:873-881. https://doi.org/10.1038/s43018-020-0096-5
2Akaike T, et al. Circulating tumor DNA correlates with Merkel cell carcinoma tumor burden and helps early detection of recurrence. ASCO, Chicago, Illinois, June 3-7, 2022.
3Eroglu Z et al. Circulating tumor DNA based molecular residual disease detection for treatment monitoring in advanced melanoma patients. Oral presentation presented at Society for Melanoma Research, Virtual Meeting, Oct 28-31, 2021.